Loading

Social Consumption

  • by NORML May 2, 2018

    Maine lawmakers have voted overwhelmingly to override Republican Gov. Paul LePage’s veto of LD 1719; the enactment of the legislation establishes a framework for the retail sale of marijuana to adults, but also amends numerous provisions of the 2016 voter-approved measure — including those specific to home grow limits and taxation.

    Specifically, LD 1719 limits the number of mature plants an adult may cultivate at home from six to three. The measure also repeals language permitting the establishment of social-use facilities, and increases the excise tax rates on the sale of wholesale marijuana products. It also makes it easier for communities that wish to ban adult use operations to do so.

    However, the measure also permits state regulators for the first time to move forward with the establishment of rules permitting for the commercial production and retail sale of cannabis to adults. Legislators anticipate that it will be until 2019 before these facilities are operational.

    Governor LePage, an ardent opponent of the 2016 initiative, vetoed LD 1719 last week, opining that he, “in good conscience cannot support a law that, on its face, violates federal law.” The Governor had previously vetoed a less conservative implementation bill last November. That bill did not amend home cultivation limits and did not outright ban social use establishments.

    NORML Deputy Director Paul Armentano expressed mixed emotions about the law’s passage. “On the one hand, we are grateful that regulators can now — after months of undue delay — finally begin moving forward with the process of licensing adult use marijuana sales and regulating this retail market. On the other hand, it is unfortunate that lawmakers felt it necessary to amend and repeal other important provisions of Question 1, the Marijuana Legalization Act, in what ultimately was futile effort to curry favor with the Governor,” he said. “At the end of the day, this measure is far from consistent with the language that the majority of voters approved at the ballot box.”

  • by Paul Armentano, NORML Deputy Director January 30, 2018

    Long-term exposure to cannabis smoke is not associated with adverse effects on pulmonary function, according to clinical data published in the journal Chronic Obstructive Pulmonary Diseases.

    A team of investigators led by researchers at the Colorado School of Public Health assessed the relationship between marijuana use and respiratory function and symptoms in a cohort of 2,300 subjects ages 40 to 80, many of whom also smoked tobacco.

    Authors reported, “Neither current nor former marijuana use was associated with increased risk of cough, wheeze, or chronic bronchitis when compared to never marijuana users after adjusting for covariates. … Current and former marijuana smokers had significantly higher FEV1 (forced expiratory volume) … when compared to never users. … Both current and former marijuana use was associated with significantly less quantitative emphysema … when compared to never users, even after adjusting for age, … current tobacco smoking pack years, and BMI. … In agreement with other published studies, we also did not find that marijuana use was associated with more obstructive lung disease.”

    The long-term combined use of tobacco and cannabis also was not found to be associated with any additive adverse effects on the lungs. Authors concluded, “Among older adults with a history of tobacco use, marijuana use does not appear to increase risk for adverse lung function. … There may be no to little increased risk of marijuana use for a further increase in respiratory symptoms or adverse effects on lung function among those with a history of concomitant tobacco use.”

    Prior longitudinal studies assessing the effects of long-term cannabis smoke exposure on lung function have similarly reported that subjects’ marijuana use history is not positively associated with increased incidences of chronic obstructive pulmonary disease (COPD), lung cancer, or with other significant detrimental effects on pulmonary function.

    Full text of the study, “Marijuana use associations with pulmonary symptoms and function in tobacco smokers enrolled in the subpopulations and intermediate outcome measures in COPD Study (SPIROMICS),” appears online here.

  • by Paul Armentano, NORML Deputy Director January 2, 2018

    Legalization in DCNeither the occasional nor the heavy use of marijuana by adolescents is associated with decreased motivation, according to clinical data published online ahead of print in the journal Substance Use & Misuse.

    A team of Florida International University researchers assessed the relationship between cannabis use and motivation in 79 adolescent subjects. Participants consisted of both long-term regular consumers and occasional users. Investigators assessed subjects’ motivational tendencies through the use of two validated tools, the Apathy Evaluation Scale and the Motivation and Engagement Scale.

    Authors reported: “After controlling for confounds, no significant differences were observed between regular and light users on any motivation index. Similarly, no associations between motivation and lifetime or past 30-day cannabis use amount were observed.”

    They concluded, “Our findings do not support a link between reduced motivation and CU among adolescents after controlling for relevant confounds.”

    An abstract of the study, “Is cannabis use associated with various indices of motivation among adolescents?”, appears here.

  • by NORML November 22, 2017

    turkey-jointWe have much to be thankful for this year. Lawmakers in 26 states have passed legislation to advance cannabis reform, including New Hampshire becoming the 22nd state to decriminalize marijuana and West Virginia becoming the 30th state to pass a medical marijuana program.

    This progress has come as a result of years of organizing and conversations with our fellow citizens about the role of government in relationship to a plant. Having the tough conversations about the scope of the government’s right to stop, search, and incarcerate individuals for possessing or consuming marijuana for either personal or medical benefits.

    And now for the first time ever, Gallup polling recorded outright majorities of Democrats, Republicans, and Independents supporting the legalization of marijuana. The only way to find out if this includes your aunts, uncles, cousins, and other relatives is if you bring it up.

    So use us as a resource – NORML.org has FactsheetsTalking Points, and you can even pass your phone or computer around the table to have your friends and family contact their lawmakers right then and there to support reform in our Action Center.

    As we look toward an uncertain future, we know we must work to both sustain our existing gains and to win future victories. With your continued financial support, we are confident that we can bring the era of marijuana prohibition to an end and usher in the new era of legalization. Together, we will be unstoppable. Together, we WILL legalize marijuana across this great country.

    From all of us at NORML to all of you, we hope you have a hempy and happy Thanksgiving.

    Onward.

     

  • by Paul Armentano, NORML Deputy Director October 20, 2017

    Medical marijuanaAdults with a history of cannabis use are less likely to suffer from non-alcoholic fatty liver disease (NAFLD) than are those who have not used the substance, according to data published online in the journal PLoS One. Non-alcoholic fatty liver disease is the most prevalent form of liver disease, affecting an estimated 80 to 100 million people in the United States.

    An international team of researchers from Stanford University in California and the Seoul National University College of Medicine in South Korea evaluated the association between marijuana and NAFLD in a nationally representative sample of over 22,000 adults. Researchers reported that cannabis use independently predicted a lower risk of suspected NAFLD in a dose-dependent manner.

    “Active marijuana use provided a protective effect against NAFLD independent of known metabolic risk factors,” authors determined. “[W]e conclude that current marijuana use may favorably impact the pathogenesis of NAFLD in US adults.”

    The findings are similar to those of a prior study published in the same journal in May. In that study, authors reported that frequent consumers of cannabis were 52 percent less likely to be diagnosed with NAFLD as compared to non-users, while occasional consumers were 15 percent less likely to suffer from the disease.

    Separate data published online earlier this month in the Journal of Viral Hepatitis also concluded that daily cannabis use is independently associated with a reduced prevalence of fatty liver disease in patients co-infected with HIV and hepatitis C.

    Full text of the study, “Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States,” appears online here.

Page 1 of 212